Bertrand Leo Chenard

This inventor holds 62 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Compositions (CPC class C07D). Top assignees: Pfizer Corporation, Hydra Biosciences, Inc., Neurogen Corporation. Active years: 1993-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bertrand Leo Chenard. Retrieved from https://idiyas.com/inventor/bertrand-leo-chenard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 62 (Patent Applications = 11)

% Patents Active = 82.3

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 12)

Average Co-Inventor Count = 2.0

ph-index = 13

Forward Citations = 586(Granted Patents)

Forward Citations (Not Self Cited) = 522(Dec 10, 2025)

Inventors with similar research interests:

Location History:

New York, NY (US) (1997)
Waterford, CT (US) (1993 - 2024)

Company Filing History:

Hydra Biosciences, Inc.

Eli Lilly and Company

Novartis International Pharmaceutical, Ltd.

patents

7. 1 out of 1,561

Boehringer Ingelheim International Gmbh

patents

8. 1 out of 6

Exithera Pharmaceuticals, Inc.

patents

9. 1 out of 1

Exlthera Pharmaceuticals, Inc.

patent

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

Areas of Expertise:

Therapeutic Compounds

Xanthine Derivatives

Ion Channel Inhibition

AMPA Antagonists

CNS Treatments

Stroke Treatments

Pyrimidine Analogues

Quinazoline Derivatives

Piperazine Analogues

Biaryl Compounds

Receptor Modulators

NMDA Antagonists

62 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435061 - Compounds and compositions for use in treating skin disorders (2025-10-07),

2. 12152014 - Therapeutic compounds and compositions (2024-11-26),

3. 11958854 - Substituted xanthines and methods of use thereof (2024-04-16),

4. 11807621 - Compounds and compositions for use in treating skin disorders (2023-11-07),

5. 11691962 - Therapeutic compounds and compositions (2023-07-04),

6. 11208409 - Substituted xanthines and methods of use thereof (2021-12-28),

7. 10519158 - Inhibiting the transient receptor potential A1 ion channel (2019-12-31),

8. 10428072 - Inhibiting the transient receptor potential A1 ion channel (2019-10-01),

9. 10399982 - Substituted xanthines and methods of use thereof (2019-09-03),

10. 10329292 - Substituted xanthine derivatives (2019-06-25),

11. 10221177 - Inhibiting the transient receptor potential A1 ion channel (2019-03-05),

12. 9969736 - Substituted xanthines and methods of use thereof (2018-05-15),

13. 9745272 - Quinazoline-2,4(1 H,3H)-dione derivatives (2017-08-29),

14. 9447114 - Thieno- and furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives (2016-09-20),

15. 9440983 - Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives (2016-09-13),

Title: Bertrand Leo Chenard - Innovative Inventor from Waterford

Introduction: Bertrand Leo Chenard is a renowned inventor based in Waterford, CT, known for his groundbreaking contributions to various industries.

Latest Patents: Bertrand Leo Chenard holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise.

Career Highlights: Throughout his career, Bertrand Leo Chenard has been recognized for his innovative solutions that have revolutionized the way we approach everyday challenges. His inventions have significantly impacted the lives of many around the world.

Collaborations: Bertrand Leo Chenard has collaborated with leading research institutions, universities, and companies to further develop and implement his inventions on a global scale. His collaborative efforts have led to the successful commercialization of several groundbreaking technologies.

Conclusion: Bertrand Leo Chenard's passion for innovation and dedication to creating a positive impact through his inventions make him a true pioneer in the world of technology and beyond.

Profile summary based on public USPTO records.